Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2014; 20(12): 3100-3111
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3100
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3100
Table 2 Prospective studies of stereotactic body radiation therapy for hepatocellular carcinoma and other liver tumors
| Ref. | Country | Patient number | Median volume, mL | Median size, cm | Median dose (range)/fraction, Gy | Median follow-up (range), mo | Local control | Overall survival |
| Cárdenes et al[29] | United States (Indiana) | 17 | 34(8-95) | - | VariableCP-A: 36-48 Gy/3 frCP-B: 40 Gy/5 fr | 24(10-42) | 100% | 75% (1 yr)60% (2 yr) |
| Andolino et al[37] | United States (Indiana) | 60 | 29(2-112) | 3.2(1-6.5) | FixedCP-A: 44 Gy/3 frCP-B: 40 Gy/5 fr | 27(2-52) | 90% (2 yr) | 67% (2 yr) |
| Bujold et al[30] | Canada | 102 | 117(1-1913) | 7.2(1.4-23.1) | Variable36 (24-54) Gy/6 fr | 31(2-36) | 87% (1 yr) | Median 17 mo |
| Kang et al[31] | South Korea | 47 | 15(2-213) | 2.9(1.3-7.8) | 57 (42-60) Gy/3 fr | 17(6-38) | 95% (2 yr) | 69% (2 yr) |
| (Korea Inst. of Radiological and Medical Sciences) |
- Citation: Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3100-3111
- URL: https://www.wjgnet.com/1007-9327/full/v20/i12/3100.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i12.3100